Latest Breaking News On - Clayb siegall - Page 1 : comparemela.com

Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying - Astrotech (NASDAQ:ASTC)

United statesDanh wilksMatthew wilksRaymond jamesFrankm svobodaClayb siegallWilma burdisThomas wiley wilkinsonLance turnerProfrac holdingGl coAstrotech corpGlobe life incProfrac holding corpImmunome incAstrotech corporation

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Clayb siegallImmunome incExchange commissionAyala pharmaceuticals incCompletes acquisitionDesmoid tumorsAyala pharmaceuticalsChief executive officerDrug administrationExchange actPrivate securities litigation reform actAnnual reportQuarterly report

Immunome Inc (IMNM) To Acquire AL102

Immunome Inc (IMNM) To Acquire AL102
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Clayb siegallImmunome incAyala pharmaceuticalsDrug administrationAyala pharmaceuticals incA gp alliance global partnersChief executive officerOrphan drug designationAlliance global partners

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

– AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile – .

Clayb siegallA gp alliance global partnersAyala pharmaceuticals incDrug administrationAyala pharmaceuticalsImmunome incExchange commissionChief executive officerOrphan drug designationAlliance global partnersFast track designationExchange actPrivate securities litigation reform actAnnual reportQuarterly report

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

- Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs.

San diegoUnited statesNew yorkClayb siegallImmunome incPharmaceuticals incZentalis pharmaceuticals incExchange commissionChief executive officerCam gallagherZentalis pharmaceuticalsExchange actPrivate securities litigation reform actAnnual reportQuarterly report